92 articles
GLP-1 weight loss drugs like Ozempic and Mounjaro deliver dramatic results, but new research reveals they may weaken bones and strip muscle mass.
New research challenges the weight-loss narrative around GLP-1 drugs like Ozempic and Wegovy, revealing they may protect the heart, brain, and addiction...
GLP-1 medications like Ozempic and Mounjaro were designed for diabetes and obesity, but new research shows they may help treat at least 10 other conditions,...
Retatrutide, a groundbreaking triple-receptor drug, targets three metabolic pathways simultaneously to deliver unprecedented weight loss results.
A new three-year study is investigating whether GLP-1 weight loss drugs like Wegovy and Zepbound can reduce cancer risk by targeting obesity-related pathways.
New 2026 research shows semaglutide and tirzepatide can directly repair cartilage damage independent of weight loss, but GLP-1 users face a higher osteoporosis...
Millennial celebrities reveal mixed experiences with weight loss drugs like Ozempic and Mounjaro, from dramatic transformations to severe side effects.
Weight loss drugs like Wegovy and Mounjaro help people shed pounds, but experts say it's unclear whether they actually reduce cancer risk.
Weight loss unlocks unexpected benefits beyond appearance: sharper brain function, better sleep, improved taste, clearer skin, and stronger immunity.
The obesity drug market is projected to grow from $19.6 billion in 2025 to $104.9 billion by 2035.
Tirzepatide (Mounjaro, Zepbound) produces 5.4% more weight loss than semaglutide (Ozempic, Wegovy) by targeting two appetite hormones instead of one.
A Cleveland Clinic study of nearly 8,000 patients reveals that 45% keep weight off after stopping GLP-1 drugs by switching treatments or lifestyle changes,...
Major insurers including the University of Missouri are cutting GLP-1 weight loss drug coverage to control costs, leaving millions without access despite...
Researchers are discovering that obesity isn't one-size-fits-all. GLP-1 drug failures are revealing dozens of distinct obesity types, each requiring...
Even with healthy habits, some fat deposits resist loss due to genetics, hormones, and receptor patterns in fat cells.
Major weight loss drugs deliver impressive results, but WHO-commissioned research reveals gaps in long-term safety data and heavy pharmaceutical industry...
GLP-1 medications like semaglutide and tirzepatide show emerging benefits for mood, cognitive function, and substance use beyond weight management.
A new semaglutide injection matched the effectiveness of the reference drug, with over 90% of participants achieving clinically meaningful weight loss in a...
New research shows waist size predicts heart failure risk better than BMI, with inflammation accounting for about 25% of the link.
Vanderbilt researchers discovered that semaglutide-induced weight loss unfolds in three distinct phases with different metabolic patterns.
GLP-1 medications like Ozempic reduce depression by 44% and anxiety by 38%, plus cut substance use disorders by 47%, according to a large Swedish study of...
Yes, some people lose weight without strict diets by making small lifestyle changes like eating slowly and choosing fiber-rich foods.
Tirzepatide achieves up to 22.5% weight loss versus 15% for semaglutide by targeting two hormone pathways instead of one. Here's why doctors are taking notice.
Modern weight loss apps cut logging time by 95% using AI photo scanning, boosting adherence rates that directly predict success.
GLP-1 medications help women lose weight fast, but rapid fat loss can trigger muscle loss too. Here's how to protect lean muscle during treatment.
New research shows wearable devices combined with blood tests can detect insulin resistance with 80% accuracy, catching metabolic problems years earlier than...
New research reveals GLP-1 drugs like tirzepatide work for rare genetic obesity caused by MC4R deficiency, offering hope for patients with limited treatment...
A Cleveland Clinic study of nearly 8,000 patients shows stopping GLP-1 drugs doesn't always trigger major weight regain. Here's what the data actually reveals.
About 1 in 10 people taking GLP-1 weight-loss drugs like Zepbound are nonresponders, losing less than 5% of body weight.
Sustainable weight loss requires a moderate calorie deficit of 300-500 daily, not extreme restriction.
From Oprah to Serena Williams, A-listers are openly discussing weight loss medications, shifting how millions view obesity treatment and challenging outdated...
New weight loss drugs like semaglutide have surged 100-fold since 2018, causing bariatric surgery rates to plummet 46% by 2025.
New research shows GLP-1 drugs and bariatric surgery improve body composition by reducing fat while preserving lean muscle.
Over 3,100 lawsuits allege GLP-1 drugs like Ozempic and Wegovy caused serious injuries including stomach paralysis and vision loss.
GLP-1 weight loss medications like Ozempic and Wegovy show surprising effects on sexual health, boosting testosterone and erectile function in men while...
People taking GLP-1 weight loss drugs risk nutritional deficiencies and muscle loss without proper guidance.
Weight management success requires balanced eating, regular exercise, and behavior changes—but experts reveal the often-overlooked component that determines...
New research shows patients tolerate significant gastrointestinal side effects from semaglutide if the drug delivers real weight loss.
South Korea's weight loss market is projected to double to $11.3 billion by 2035, driven by cultural pressures and lifestyle changes.
Medically supervised fasting produces 0.8-13% weight loss and improves insulin sensitivity comparable to diabetes drugs.
A new study reveals that SNAC, the ingredient enabling Wegovy and Ozempic pills to work, may alter gut bacteria and trigger inflammation.
GLP-1 medication costs are dropping 15% in 2026, yet overall spending could jump 10% due to rising usage. Here's what employers and patients need to know.
80% of people regain weight within 5 years—and a neuroscientist says medications alone won't fix it. Here's what lasting weight loss actually requires.
New Lancet guidelines shift obesity diagnosis from BMI alone to clinical disease markers. Here's why doctors say the change matters for treatment decisions.
MCT oil boosts metabolism and fat burning, but studies show modest weight loss effects. Here's what actually works and what's overhyped.
A long-term study reveals ketogenic diets prevent weight gain but trigger fatty liver disease and dangerous blood sugar spikes. Here's what researchers found.
People regain weight faster after stopping GLP-1 medications than other weight loss methods—averaging 2 pounds monthly.
Intermittent fasting doesn't beat regular calorie restriction for weight loss, but it may help some people stick to their goals.
Research shows most people who lose weight quickly regain it—and sometimes more. Here's what science says about sustainable weight loss versus crash diets.
A comprehensive Cochrane review of 22 studies shows intermittent fasting produces similar weight loss to regular dieting—but experts say the findings may be misleading.
